Advertisement

Chemoprevention in Prostate Cancer

  • Chadi Nabhan
  • Raymond Bergan
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 106)

Abstract

Prostate cancer is the most frequently diagnosed malignancy in American men. It will be diagnosed in an estimated 180,400 Americans in 2000, causing death in approximately 31,900 (1). World wide, these numbers are much higher (1). Even in those who do not die from disease, treatment is associated with significant morbidity (2). There are a number of features particular to prostate cancer which make it an ideal disease model for the development and implementation of effective chemopreventive approaches. It is a disease characterized by a long latency period. Stages within this latency period are relatively well characterized, and can be detected clinically. In addition to the high incidence of prostate cancer in Western countries, its clinical course is very consistent. Finally, data from epidemiologic studies is consistent with the notion that pharmacologic intervention can in fact favorably affect the incidence of prostate cancer. The ability to effectively prevent the occurrence and/or the progression of prostate cancer would have a significant clinical impact. This chapter first provides a review of chemoprevention strategies, and then goes on to discuss relevant biochemistry, epidemiology and specific chemopreventive agents, and their associated mechanisms of action, as they relate to prostate cancer.

Keywords

Prostate Cancer Epidermal Growth Factor Receptor Prostate Specific Antigen Benign Prostatic Hyperplasia Prostate Cancer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer Statistics, 2000, CA Cancer J Clin.50: 7–33, 2000.PubMedGoogle Scholar
  2. 2.
    Oesterling, J. E., Fuks, Z., Lee, C. T., and Scher, H. I. Cancer of the Prostate. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), CANCER: Principals and Practice of Oncology, 5th edition, Vol. 1, pp. 1322–1385. New York: Lippincott-Raven, 1997.Google Scholar
  3. 3.
    Friberg, S. and Mattson, S. On the growth rates of human malignant tumors: implications for medical decision making, J Surg Oncol.65: 284–97, 1997.PubMedGoogle Scholar
  4. 4.
    Spratt, J. S., Ter-Pogossian, M., and Long, R. T. L. The detection and growth of intrathoracic neoplasms, Arch. Surg.86: 283–288, 1963.Google Scholar
  5. 5.
    Byar, D. P. and Freedman, L. S. The importance and nature of cancer prevention trials, Semin Oncol./7.. 413–24, 1990.Google Scholar
  6. 6.
    Oefelein, M. G., Kaul, K., Herz, B., Blum, M. D., Holland, J. M., Keeler, T. C., Cook, W. A., and Ignatoff, J. M. Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy [see comments], J Urol.155: 238–42, 1996.PubMedGoogle Scholar
  7. 7.
    Raj, G. V., Moreno, J. G., and Gomella, L. G. Utilization of polymerase chain reaction technology in the detection of solid tumors [see comments], Cancer.82: 1419–42, 1998.PubMedGoogle Scholar
  8. 8.
    Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., and Trump, D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer [see comments], N Engl J Med.341: 1781–8, 1999.PubMedGoogle Scholar
  9. 9.
    DAmico, A. V., Whittington, R., Malkowicz, S. B., Fondurulia, J., Chen, M. H., Kaplan, I., Beard, C. J., Tomaszewski, J. E., Renshaw, A. A., Wein, A., and Coleman, C. N. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer, J Clin Oncol.17: 168–72, 1999.Google Scholar
  10. 10.
    Dillioglugil, 0., Leibman, B. D., Kattan, M. W., Seale-Hawkins, C., Wheeler, T. M., and Scardino, P. T. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer, Urology.50: 93–9, 1997.PubMedGoogle Scholar
  11. 11.
    Kattan, M. W., Eastham, J. A., Stapleton, A. M., Wheeler, T. M., and Scardino, P. T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer, J Natl Cancer Inst.90: 766–71, 1998.PubMedGoogle Scholar
  12. 12.
    Kattan, M. W., Wheeler, T. M., and Scardino, P. T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer, J Clin Oncol.17.1499–507, 1999.PubMedGoogle Scholar
  13. 13.
    Bostwick, D. G. Prostatic intraepithelial neoplasia is a risk factor for cancer, Semin Urol Oncol.17: 187–98, 1999.PubMedGoogle Scholar
  14. 14.
    Dickson, R. B. and Lippman, M. E. Cancer of the Breast. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), CANCER: Principals and Practice of Oncology, 5th edition, Vol. 2, pp. 1541–1617. New York: Lippincott-Raven, 1997.Google Scholar
  15. 15.
    Cohen, A. M., Minsky, B. D., and Schilsky, R. L. Cancer of the Colon. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), CANCER: Principals and Practice of Oncology, 5th edition, Vol. 1, pp. 1144–1197. New York: Lippincott-Raven, 1997.Google Scholar
  16. 16.
    Moinpour, C. M., Lovato, L. C., Thompson, I. M., Jr., Ware, J. E., Jr., Ganz, P. A., Patrick, D. L., Shumaker, S. A., Donaldson, G. W., Ryan, A., and Coltman, C. A., Jr. Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors, J Clin Oncol.18: 1942–53, 2000.PubMedGoogle Scholar
  17. 17.
    Recruiting black men to a clinical trial to evaluate prostate cancer screening--Detroit, Michigan, 1998, MMWR Morb Mortal Wkly Rep. 47: 694–6, 1998.Google Scholar
  18. 18.
    Hoffman-Goetz, L., Breen, N. L., and Meissner, H. The impact of social class on the use of cancer screening within three racial/ethnic groups in the United States, Ethn Dis.8: 43–51, 1998.Google Scholar
  19. 19.
    Freeman, H. P. The impact of clinical trial protocols on patient care systems in a large city hospital. Access for the socially disadvantaged, Cancer.722834–8, 1993Google Scholar
  20. 20.
    Vernon, S. W., Vogel, V. G., Halabi, S., Jackson, G. L., Lundy, R. 0., and Peters, G. N. Breast cancer screening behaviors and attitudes in three racial/ethnic groups, Cancer.69: 165–74, 1992.PubMedGoogle Scholar
  21. 21.
    Saki, W. A., Haas, G. P., Cassin, B. F., Pontes, J. E., and Crissman, J. D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients [see comments], J Urol.150: 379–85, 1993.Google Scholar
  22. 22.
    Meydani, M. Vitamin E [see comments], Lancet.345: 170–5, 1995.PubMedGoogle Scholar
  23. 23.
    Bergan, R., Kyle, E., Nguyen, P., Trepel, J., lngui, C., and Neckers, L. Genisteinstimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta- 1-integrin, Clin Exp Metastasis.14: 389–98, 1996.PubMedGoogle Scholar
  24. 24.
    Singh, D. K. and Lippman, S. M. Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents, Oncology (Huntingt)121787–800; discussion 1802–1805, 1998Google Scholar
  25. 25.
    De Flora, S., Bennicelli, C., and Bagnasco, M. Rationale and mechanisms of cancer chemoprevention, Recent Results Cancer Res.151: 29–44, 1999.PubMedGoogle Scholar
  26. 26.
    Cleaver, J. E. Defective repair replication of DNA in xeroderma pigmentosum, Nature.218: 652–6, 1968.PubMedGoogle Scholar
  27. 27.
    Kraemer, K. H., DiGiovanna, J. J., and Peck, G. L. Chemoprevention of skin cancer in xeroderma pigmentosum, J Dermatol.19: 715–8, 1992.PubMedGoogle Scholar
  28. 28.
    Fearon, E. R. and Vogelstein, B. A genetic model for colorectal tumorigenesis, Cell.61: 759–67, 1990.PubMedGoogle Scholar
  29. 29.
    Kraemer, K. H., DiGiovanna, J. J., Moshell, A. N., Tarone, R. E., and Peck, G. L. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin, N Engl J Med.318: 1633–7, 1988.PubMedGoogle Scholar
  30. 30.
    DiGiovanna, J. J. Retinoid chemoprevention in the high-risk patient, J Am Acad Dermatol.39: S82–5, 1998.Google Scholar
  31. 31.
    Willett, W. C., Polk, B. F., Morris, J. S., Stampfer, M. J., Pressel, S., Rosner, B., Taylor, J. O., Schneider, K., and Hames, C. G. Prediagnostic serum selenium and risk of cancer, Lancet. 2.. 130–4, 1983.PubMedGoogle Scholar
  32. 32.
    Clark, L. C., Combs, G.F.Jr., Turnbull, B. W., Slate, E. H., Chalker, D. K., Chow, J., Davis, L. S., Glover, R. A., Graham, G. F., Gross, E. G., Krongrad, A., Lesher, J. L.Jr., Park, H. K., Sanders, B. B., Jr., Smith, C. L., and Taylor, J. R.Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group [see comments] [published erratum appears in JAMA 1997 May 21;277(191:1520], Jama.2761957–63,1996Google Scholar
  33. 33.
    Kyle, E., Neckers, L., Takimoto, C., Curt, G., and Bergan, R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity, Mol Pharmacol.51: 193–200, 1997.PubMedGoogle Scholar
  34. 34.
    Adlercreutz, H. Western diet and Western diseases: some hormonal and biochemical mechanisms and assocaitions, Scand. J. Clin. Lab Invest.50 Suppl 201: 3–23, 1990.Google Scholar
  35. 35.
    Severson, R. K., Nomura, A. M., Grove, J. S., and Stemmermann, G. N. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii., Cancer Res.49(7)1857–60, 1989.PubMedGoogle Scholar
  36. 36.
    Liu, Y. Q., Kyle, E., Lieberman, R., Crowell, J., Kelloff, G., and Bergan, R. C. Focal adhesion kinase(FAK) phosphorylation is not required for genistein-induced FAK-b1 -integrin complex formation, Clinical and Experimental Metastasis. submitted.2000.Google Scholar
  37. 37.
    Bergan, R. C. and Slichenmyer, W. Tyrosine Kinase Inhibitors and Signal Transduction Modulators: Rationale and Current Status as Chemopreventive Agents for Prostate Cancer, Urology.In Press: 2000.Google Scholar
  38. 38.
    Liu, Y. Q., Kyle, E., Patel, S., Housseau, F., Hakim, F., Lieberman, R., Pins, M., Blagosklonny, M., and Bergan, R. C.Prostate Cancer Chemoprevention Agents Exhibit Selective Activity Against Early Stage Prostate Cancer CellsProstate Cancer and Diseases of the Prostate.submitted: ,2000.Google Scholar
  39. 39.
    Thompson, I. M., Coltman, C. A., Jr., and Crowley, J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial, Prostate. 33: 217–21, 1997.PubMedGoogle Scholar
  40. 40.
    Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [see comments], J Natl Cancer Inst.90: 1371–88, 1998.PubMedGoogle Scholar
  41. 41.
    Kimball, C. P. Non-cooperation: An examination of factors leading to non-compliance in a hypertensive clinic, Psychiatric Journal of the University of Ottawa. 5: 243–249, 1981.Google Scholar
  42. 42.
    Becker, M. H., Maiman, L. A., Kirscht, J. P., and.al, e. Patient perceptions and compliance. In: R. B. Haynes, D. W. Taylor, and D. L. Sackett (eds.), Compliance in Health Care, pp. 78–109. Baltimore: Johns Hopkins Press, 1981.Google Scholar
  43. 43.
    Haynes, R. B. The disease and the mechanics of treatment. In: R. B. Haynes, D. W. Taylor, and D. L. Sackett (eds.), Compliance in Health Care, pp. 49–62. Baltimore: Johns Hopkins Press, 1981.Google Scholar
  44. 44.
    Coltman, C. A., Jr., Thompson, I. M., Jr., and Feigl, P. Prostate Cancer Prevention Trial (PCPT) update, Eur Urol.35: 544–7, 1999.PubMedGoogle Scholar
  45. 45.
    Kelloff, G. J., Sigman, C. C., Johnson, K. M., Boone, C. W., Greenwald, P., Crowell, J. A., Hawk, E. T., and Doody, L. A. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer, Cancer Epidemiol Biomarkers Prey.9: 127–37, 2000.Google Scholar
  46. 46.
    Kosmeder, J. W. and Pezzuto, J. M. Intermediate Biomarkers. In: R. C. Bergan (ed.) Cancer Chemoprevention, 2000.Google Scholar
  47. 47.
    Takimoto, C. Basic Pharmacokinetics and Pharmacodynamic Principals. In: R. C. Bergan (ed.) Cancer Chemoprevention, 2000.Google Scholar
  48. 48.
    von Eschenbach, A., Ho, R., Murphy, G. P., Cunningham, M., and Lins, N. American Cancer Society guidelines for the early detection of prostate cancer: update, June 10, 1997, Cancer.80.. 1805–7, 1997.Google Scholar
  49. 49.
    Spitz, M. R., Currier, R. D., Fueger, J. J., Babaian, R. J., and Newell, G. R. Familial patterns of prostate cancer: a case-control analysis, J Urol.146.. 1305–7, 1991.PubMedGoogle Scholar
  50. 50.
    Carter, B. S., Beaty, T. H., Steinberg, G. D., Childs, B., and Walsh, P. C. Mendelian inheritance of familial prostate cancer, Proc Natl Acad Sci U S A.89: 3367–71, 1992.PubMedGoogle Scholar
  51. 51.
    Gronberg, H., Damber, L., and Damber, J. E. Familial prostate cancer in Sweden.A nationwide register cohort study, Cancer. 77: 138–43, 1996.Google Scholar
  52. 52.
    Smith, J. R., Freije, D., Carpten, J. D., Gronberg, H., Xu, J., Isaacs, S. D., Brownstein, M. J., Bova, G. S., Guo, H., Bujnovszky, P., Nusskern, D. R., Damber, J. E., Bergh, A., Emanuelsson, M., Kallioniemi, 0. P., Walker-Daniels, J., Bailey-Wilson, J. E., Beaty, T. H., Meyers, D. A., Walsh, P. C., Collins, F. S., Trent, J. M., and Isaacs, W. B. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search [see comments] Science.2741371–4, 1996.PubMedGoogle Scholar
  53. 53.
    Xu, J., Meyers, D., Freije, D., Isaacs, S., Wiley, K., Nusskern, D., Ewing, C., Wilkens, E., Bujnovszky, P., Bova, G. S., Walsh, P., Isaacs, W., Schleutker, J., Matikainen, M., Tammela, T., Visakorpi, T., Kallioniemi, 0. P., Berry, R., Schaid, D., French, A., McDonnell, S., Schroeder, J., Blute, M., Thibodeau, S., Trent, J.and et al. Evidence for a prostate cancer susceptibility locus on the X chromosome Nat Genet.20175–9, 1998PubMedGoogle Scholar
  54. 54.
    Brawley, 0. W. and Thompson, I. M. The chemoprevention of prostate cancer and the Prostate Cancer Prevention Trial, Cancer Treat Res.88: 189–200, 1996.PubMedGoogle Scholar
  55. 55.
    Mebane, C., Gibbs, T., and Horm, J. Current status of prostate cancer in North American black males, J Natl Med Assoc.82: 782–8, 1990.PubMedGoogle Scholar
  56. 56.
    Steele, G. D., Jr., Osteen, R. T., Winchester, D. P., Murphy, G. P., and Menck, H. R. Clinical highlights from the National Cancer Data Base: 1994 [see comments], CA Cancer J Clin.44: 71–80, 1994.PubMedGoogle Scholar
  57. 57.
    Davidson, D., Bostwick, D. G., Qian, J., Wollan, P. C., Oesterling, J. E., Rudders, R. A., Siroky, M., and Stilmant, M. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies, J Urol.154: 1295–9, 1995.PubMedGoogle Scholar
  58. 58.
    Keetch, D. W., Humphrey, P., Stahl, D., Smith, D. S., and Catalona, W. J. Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate, J Urol.154: 347–51, 1995.PubMedGoogle Scholar
  59. 59.
    Brawer, M. K., Bigler, S. A., Sohlberg, 0. E., Nagle, R. B., and Lange, P. H. Significance of prostatic intraepithelial neoplasia on prostate needle biopsyUrology 38103–7, 1991.PubMedGoogle Scholar
  60. 60.
    Markham, C. W. Prostatic intraepithelial neoplasia: detection and correlation with invasive cancer in fine-needle biopsy, Urology. 34: 57–61, 1989.PubMedGoogle Scholar
  61. 61.
    Huncharek, M. and Muscat, J. Genetic characteristics of prostate cancer, Cancer Epidemiol Biomarkers Prey. 4: 681–7, 1995.Google Scholar
  62. 62.
    Sherwood, E. R., Theyer, G., Steiner, G., Berg, L. A., Kozlowski, J. M., and Lee, C. Differential expression of specific cytokeratin polypeptides in the basal and lumina] epithelia of the human prostate, Prostate.18: 303–14, 1991.PubMedGoogle Scholar
  63. 63.
    Bonkhoff, H., Stein, U., and Remberger, K. The proliferative function of basal cells in the normal and hyperplastic human prostate, Prostate.24: 114–8, 1994.PubMedGoogle Scholar
  64. 64.
    Leav, I., McNeal, J. E., Kwan, P. W., Komminoth, P., and Merk, F. B. Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study, Prostate.29: 137–45, 1996.PubMedGoogle Scholar
  65. 65.
    Bonkhoff, H. and Remberger, K. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate, V irchows Arch A Pathol Anat Histopathol.422: 35–8, 1993.Google Scholar
  66. 66.
    Ibrahim, G. K., Kerns, B. J., MacDonald, J. A., Ibrahim, S. N., Kinney, R. B., Humphrey, P. A., and Robertson, C. N. Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues, J Urol.149: 170–3, 1993.PubMedGoogle Scholar
  67. 67.
    Myers, R. B., Srivastava, S., Oelschlager, D. K., and Grizzle, W. E. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma [see comments], J Natl Cancer Inst.86: 1140–5, 1994.PubMedGoogle Scholar
  68. 68.
    Giri, D. K., Wadhwa, S. N., Upadhaya, S. N., and Talwar, G. P. Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study, Prostate.23: 329–36, 1993.PubMedGoogle Scholar
  69. 69.
    Fiorelli, G., De Bellis, A., Longo, A., Giannini, S., Natali, A., Costantini, A., Vannelli, G. B., and Serio, M. Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog, J Clin Endocrinol Metab.72: 740–6, 1991.PubMedGoogle Scholar
  70. 70.
    English, H. F., Santen, R. J., and Isaacs, J. T. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement, Prostate.11: 229–42, 1987.PubMedGoogle Scholar
  71. 71.
    Turbat-Herrera, E. A., Herrera, G. A., Gore, I., Lott, R. L., Grizzle, W. E., and Bonnin, J. M. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study, Arch Pathol Lab Med.112: 1100–5, 1988.Google Scholar
  72. 72.
    Harper, M. E., Glynne-Jones, E., Goddard, L., Mathews,P., and Nicholson, R. I. Expression of androgen receptor and growth factors in premalignant lesions of the prostate, J Pathol.186: 169–77, 1998.PubMedGoogle Scholar
  73. 73.
    Haussler, O., Epstein, J. I., and Amin, M. B. Cell proliferation, apoptosis, oncogenes, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer, Human Pathology.30: 1077–1086, 1999.PubMedGoogle Scholar
  74. 74.
    Colombel, M., Symmans, F., Gil, S., O’Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers, Am J Pathol.143: 390–400, 1993.PubMedGoogle Scholar
  75. 75.
    Maygarden, S. J., Strom, S., and Ware, J. L. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia, Arch Pathol Lab Med.116: 269–73, 1992.PubMedGoogle Scholar
  76. 76.
    Boag, A. H. and Young, I. D. Immunohistochemical analysis of type IV collagenase expression in prostatic hyperplasia and adenocarcinoma, Mod Pathol.6: 65–8, 1993.PubMedGoogle Scholar
  77. 77.
    Leav, I., Merk, F. B., Lee, K. F., Loda, M., Mandoki, M., McNeal, J. E., and Ho, S. M. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions, Am J Pathol.154: 863–70, 1999.PubMedGoogle Scholar
  78. 78.
    McNeal, J. E., Alroy, J., Leav, I., Redwine, E. A., Freiha, F. S., and Stamey, T. A. Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis, Am J Clin Pathol.90: 23–32, 1988.PubMedGoogle Scholar
  79. 79.
    McNeal, J. E., Haillot, O., and Yemoto, C. Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining, Prostate.27: 258–68, 1995.PubMedGoogle Scholar
  80. 80.
    Nagle, R. B., Brawer, M. K., Kittelson, J., and Clark, V. Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma, Am J Pathol.138: 119–28, 1991.PubMedGoogle Scholar
  81. 81.
    Perlman, E. J. and Epstein, J. I. Blood group antigen expression in dysplasia and adenocarcinoma of the prostate, Am J Surg Pathol.14: 810–8, 1990.PubMedGoogle Scholar
  82. 82.
    Bostwick, D. G., Dousa, M. K., Crawford, B. G., and Wollan, P. C. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma, Am J Surg Pathol.18: 1240–6, 1994.PubMedGoogle Scholar
  83. 83.
    Jarrard, D. F., Paul, R., van Bokhoven, A., Nguyen, S. H., Bova, G. S., Wheelock, M. J., Johnson, K. R., Schalken, J., Bussemakers, M., and Isaacs, W. B. P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer, Clin Cancer Res. 3: 2121–8, 1997.PubMedGoogle Scholar
  84. 84.
    Hampel, 0. Z., Kattan, M. W., Yang, G., Haidacher, S. J., Saleh, G. Y., Thompson, T. C., Wheeler, T. M., and Marcelli, M. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma.a prognostic study, J Urol.159: 2220–5, 1998.PubMedGoogle Scholar
  85. 85.
    Sweat, S. D., Pacelli, A., Bergstralh, E. J., Slezak, J. M., and Bostwick, D. G. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer, J Urol.161: 1229–32, 1999.PubMedGoogle Scholar
  86. 86.
    Maygarden, S. J., Novotny, D. B., Moul, J. W., Bae, V. L., and Ware, J. L. Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma, Mod Pathol. 7: 930–6, 1994.PubMedGoogle Scholar
  87. 87.
    Sentinelli, S. Mucins in prostatic intra-epithelial neoplasia and prostatic carcinoma, Histopathology.22: 271–4, 1993.PubMedGoogle Scholar
  88. 88.
    Nuti, M., Teramoto, Y. A., Mariani-Costantini, R., Hand, P. H., Colcher, D., and Schlom, J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations, Int J Cancer.29: 539–45, 1982.PubMedGoogle Scholar
  89. 89.
    Bonkhoff, H., Fixemer, T., Hunsicker, I., and Remberger, K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions, Am J Pathol. 155: 641–7, 1999.PubMedGoogle Scholar
  90. 90.
    Hawkins, M. J. Clinical trials of antiangiogenic agents, Curr Opin Oncol. 7: 90–3, 1995.PubMedGoogle Scholar
  91. 91.
    Bostwick, D. G., Neumann, R., Qian, J., and Cheng, L. Reversibility of prostatic intraepithelial neoplasia: implications for chemoprevention, Eur Urol.35: 492–5, 1999.PubMedGoogle Scholar
  92. 92.
    Arakawa, A., Song, S., Scardino, P. T., and Wheeler, T. M. High grade prostatic intraepithelial neoplasia in prostates removed following irradiation failure in the treatment of prostatic adenocarcinoma, Pathol Res Pract.191: 868–72, 1995.PubMedGoogle Scholar
  93. 93.
    Lyne, J. C., Melhem, M. F., Finley, G. G., Wen, D., Liu, N., Deng, D. H., and Salup, R. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro, Cancer.1 Sci Am. 3: 21–30, 1997.Google Scholar
  94. 94.
    Pisters, L. L., Troncoso, P., Zhau, H. E., Li, W., von Eschenbach, A. C., and Chung, L. W. c-met proto-oncogene expression in benign and malignant human prostate tissues, J Urol.154: 293–8, 1995.PubMedGoogle Scholar
  95. 95.
    Levine, A. J. and Momand, J. Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products, Biochem Biophys Acta.1032: 119–36, 1990.PubMedGoogle Scholar
  96. 96.
    Scher, H. I., Sarkis, A., Reuter, V., Cohen, D., Netto, G., Petrylak, D., Lianes, P., Fuks, Z., Mendelsohn, J., and Cordon-Cardo, C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms, Clin Cancer Res.1: 545–50, 1995.PubMedGoogle Scholar
  97. 97.
    McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the proto-oncogene bc1–2 in the prostate and its association with emergence of androgen-independent prostate cancer, Cancer Res.52: 6940–4, 1992.PubMedGoogle Scholar
  98. 98.
    Bostwick, D. G. and Brawer, M. K. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer, Cancer.59: 788–94, 1987.PubMedGoogle Scholar
  99. 99.
    Bostwick, D. G., Amin, M. B., Dundore, P., Marsh, W., and Schultz, D. S.Architectural patterns of high-grade prostatic intraepithelial neoplasia, Hum Pathol.24: 298–310, 1993.PubMedGoogle Scholar
  100. 100.
    Kovi, J., Jackson, M. A., and Heshmat, M. Y. Ductal spread in prostatic carcinoma,Cancer.56: 1566–73, 1985.PubMedGoogle Scholar
  101. 101.
    Kasper, S., Sheppard, P. C., Yan, Y., Pettigrew, N., Borowsky, A. D., Prins, G. S., Dodd, J. G., Duckworth, M. L., and Matusik, R. J. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer [corrected and republished in Lab Invest 1998 Jun;78(6):i-xv], Lab Invest.78: 319–33, 1998.PubMedGoogle Scholar
  102. 102.
    Garabedian, E. M., Humphrey, P. A., and Gordon, J. I. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells, Proc Natl Acad Sci USA.95: 15382–7, 1998.PubMedGoogle Scholar
  103. 103.
    McNeal, J. E. and Bostwick, D. G. Intraductal dysplasia: a premalignant lesion of the prostate, Hum Pathol./7: 64–71, 1986.Google Scholar
  104. 104.
    Qian, J., Wollan, P., and Bostwick, D. G. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma, Hum Pathol.28: 143–8, 1997.PubMedGoogle Scholar
  105. 105.
    Graham, S. D., Jr., Bostwick, D. G., Hoisaeter, A., Abrahamsson, P., Algaba, F., di Sant’Agnese, A., Mostofi, F. K., and Napalkov, P. Report of the Committee on Staging and Pathology, Cancer.70: 359–61, 1992.PubMedGoogle Scholar
  106. 106.
    Bostwick, D. G. Prostatic intraepithelial neoplasia (PIN): current concepts, J Cell Biochem Suppl 10–9, 1992.Google Scholar
  107. 107.
    Montironi, R., Galluzzi, C. M., Diamanti, L., Taborro, R., Scarpelli, M., and Pisani, E. Prostatic intra-epithelial neoplasia. Qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections, Pathol Res Pract.189: 542–8, 1993.PubMedGoogle Scholar
  108. 108.
    Sinha, A. A., Gleason, D. F., Staley, N. A., Wilson, M. J., Sameni, M., and Sloane, B. F. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis, Mat Rec.241: 353–62, 1995.Google Scholar
  109. 109.
    Hall, M. C., Navone, N. M., Troncoso, P., Pollack, A., Zagars, G. K., von Eschenbach, A. C., Conti, C. J., and Chung, L. W. Frequency and characterization of p53 mutations in clinically localized prostate cancer, Urology.45: 470–5, 1995.PubMedGoogle Scholar
  110. 110.
    Lee, F., Torp-Pedersen, S. T., Carroll, J. T., Siders, D. B., Christensen-Day, C., and Mitchell, A. E. Use of transrectal ultrasound and prostate-specific antigen in diagnosis of prostatic intraepithelial neoplasia, Urology.34: 4–8, 1989.PubMedGoogle Scholar
  111. 111.
    Cheng, L., Song, S. Y., Pretlow, T. G., Abdul-Karim, F. W., Kung, H. J., Dawson, D. V., Park, W. S., Moon, Y. W., Tsai, M. L., Linehan, W. M., Emmert-Buck, M. R., Liotta, L. A., and Zhuang, Z. Evidence of independent origin of multiple tumors from patients with prostate cancer, J Natl Cancer Inst.90: 233–7, 1998.PubMedGoogle Scholar
  112. 112.
    Foulds, L. Multiple etiologic factors in neoplastic development, Cancer Res.25: 1339–47, 1965.PubMedGoogle Scholar
  113. 113.
    Bartels, P. H., da Silva, V. D., Montironi, R., Hamilton, P. W., Thompson, D.,Vaught, L., and Bartels, H. G. Chromatin texture signatures in nuclei from prostate lesions, Anal Quant Cytol Histol.20: 407–16, 1998.PubMedGoogle Scholar
  114. 114.
    Veltri, R. W., Miller, M. C., Partin, A. W., Coffey, D. S., and Epstein, J. I. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei, Urology.48: 685–91, 1996.PubMedGoogle Scholar
  115. 115.
    Meyskens, F. L., Jr., Surwit, E., Moon, T. E., Childers, J. M., Davis, J. R., Don, R. T., Johnson, C. S., and Alberts, D. S. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-transretinoic acid: a randomized trial [see comments], J Natl Cancer Inst.86: 539–43, 1994.PubMedGoogle Scholar
  116. 116.
    Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis, N Engl J Med.328: 1313–6, 1993.PubMedGoogle Scholar
  117. 117.
    Westra, W. H. and Sidransky, D. Phenotypic and genotypic disparity in premalignant lesions: of calm water and crocodiles [editorial; comment], J Natl Cancer Inst.90: 1500–1, 1998.PubMedGoogle Scholar
  118. 118.
    Mao, L., El-Naggar, A. K., Papadimitrakopoulou, V., Shin, D. M., Shin, H. C., Fan, Y., Zhou, X., Clayman, G., Lee, J. J., Lee, J. S., Hittelman, W. N., Lippman, S. M., and Hong, W. K. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy [see comments], J Natl Cancer Inst.90: 154–551, 1998.Google Scholar
  119. 119.
    Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R., and Doody, L. A. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials, J Cell Biochem Suppl.19: 1–9, 1994.PubMedGoogle Scholar
  120. 120.
    Ronnett, B. M., Carmichael, M. J., Carter, H. B., and Epstein, J. I. Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? [see comments], J Urol.150: 386–9, 1993.PubMedGoogle Scholar
  121. 121.
    Alexander, E. E., Qian, J., Wollan, P. C., Myers, R. P., and Bostwick, D. G. Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration, Urology.47: 693–8, 1996.PubMedGoogle Scholar
  122. 122.
    Kelloff, G. J. Perspectives on cancer chemoprevention research and drug development, Adv Cancer Res.78: 199–334, 2000.PubMedGoogle Scholar
  123. 123.
    Hanks, G. E., D’Amico, A., Epstein, B. E., and Schultheiss, T. E. Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time [see comments], Int J Radiat Oncol Biol Phys.27: 125–7, 1993.PubMedGoogle Scholar
  124. 124.
    Schmid, H. P., McNeal, J. E., and Stamey, T. A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume, Cancer.71: 2031–40, 1993.PubMedGoogle Scholar
  125. 125.
    Giannulis, I., Montironi, R., Galluzzi, C. M., de Nictolis, M., and Diamanti, L. Frequency and location of mitoses in prostatic intraepithelial neoplasia (PIN), Anticancer Res.13: 2447–51, 1993.PubMedGoogle Scholar
  126. 126.
    Montironi, R., Magi Galluzzi, C., Scarpelli, M., Giannulis, I., and Diamanti, L. Occurrence of cell death (apoptosis) in prostatic intra-epithelial neoplasia, Virchows Arch A Pathol Mat Histopathol.423: 351–7, 1993.Google Scholar
  127. 127.
    Montironi, R., Magi-Galluzzi, C., and Fabris, G. Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation, Pathol Res Pract.191: 873–80, 1995.PubMedGoogle Scholar
  128. 128.
    Myers, R. B., Kudlow, J. E., and Grizzle, W. E. Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia, Mod Pathol.6: 7337, 1993.Google Scholar
  129. 129.
    Robertson, C. N., Roberson, K. M., Herzberg, A. J., Kerns, B. J., Dodge, R. K., and Paulson, D. F. Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues, Surg Oncol.3: 237–42, 1994.PubMedGoogle Scholar
  130. 130.
    Maddy, S. Q., Chisholm, G. D., Busuttil, A., and Habib, F. K. Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumour, Br J Cancer.60: 41–4, 1989.PubMedGoogle Scholar
  131. 131.
    Montone, K. T. and Tomaszewski, J. E. In situ hybridization for epidermal growth factor receptor (EGFR) external domain transcripts in prostatic adenocarcinoma, J Clin Lab Anal.7: 188–95, 1993.PubMedGoogle Scholar
  132. 132.
    Harper, M. E., Goddard, L., Glynne-Jones, E., Wilson, D. W., Price-Thomas, M., Peeling, W. B., and Griffiths, K. An immunocytochemical analysis of TGF alpha expression in benign and malignant prostatic tumors, Prostate.23: 9–23, 1993.PubMedGoogle Scholar
  133. 133.
    Cohen, D. W., Simak, R., Fair, W. R., Melamed, J., Scher, H. L., and Cordon-Cardo, C. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues, J Urol.152: 2120–4, 1994.PubMedGoogle Scholar
  134. 134.
    Kuhn, E. J., Kurnot, R. A., Sesterhenn, I. A., Chang, E. H., and Moul, J. W. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma, J Urol.150: 1427–33, 1993.PubMedGoogle Scholar
  135. 135.
    Zhau, H. E., Wan, D. S., Zhou, J., Miller, G. J., and von Eschenbach, A. C. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines, Mol Carcinog.5: 320–7, 1992.PubMedGoogle Scholar
  136. 136.
    Sikes, R. A. and Chung, L. W. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene, Cancer Res.52: 3174–81, 1992.PubMedGoogle Scholar
  137. 137.
    Sadasivan, R., Morgan, R., Jennings, S., Austenfeld, M., Van Veldhuizen, P., Stephens, R., and Noble, M. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer, J Urol.150: 126–31, 1993.PubMedGoogle Scholar
  138. 138.
    Veltri, R. W., Partin, A. W., Epstein, J. E., Marley, G. M., Miller, C. M., Singer, D. S., Patton, K. P., Criley, S. R., and Coffey, D. S. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression, J Cell Biochem Suppl.19: 249–58, 1994.PubMedGoogle Scholar
  139. 139.
    Zimmerman, C. M. and Padgett, R. W. Transforming growth factor beta signaling mediators and modulators, Gene.249: 17–30, 2000.PubMedGoogle Scholar
  140. 140.
    Sporn, M. B., Roberts, A. B., Wakefield, L. M., and de Crombrugghe, B. Some recent advances in the chemistry and biology of transforming growth factor-beta, J Cell Biol.105: 1039–45, 1987.PubMedGoogle Scholar
  141. 141.
    Sehgal, I., Baley, P. A., and Thompson, T. C. Transforming growth factor betal stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro, Cancer Res.56: 3359–65, 1996.PubMedGoogle Scholar
  142. 142.
    Kim, I. Y., Ahn, H. J., Zelner, D.J., Shaw, J. W., Sensibar, J. A., Kim, J. H., Kato, M., and Lee, C.Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells Cancer Res5644–8, 1996PubMedGoogle Scholar
  143. 143.
    Kim, I. Y., Ahn, H. J., Zelner, D. J., Shaw, J. W., Lang, S., Kato, M., Oefelein, M. G., Miyazono, K., Nemeth, J. A., Kozlowski, J. M., and Lee, C. Loss of Expression of Transforming Growth Factor II Type I and Type II Receptors Correlates with Tumor Grade in Human Prostate Cancer Tissues, Clinical Cancer Res.2: 1255–1261, 1996.Google Scholar
  144. 144.
    Kim, I. Y., Ahn, H. J., Lang, S., Oefelein, M. G., Oyasu, R., Kozlowski, J. M., and Lee, C. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients, Clin Cancer Res. 4: 1625–30, 1998.PubMedGoogle Scholar
  145. 145.
    Fudge, K., Wang, C. Y., and Stearns, M. E. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas, Mod Pathol.7: 549–54, 1994.PubMedGoogle Scholar
  146. 146.
    Fudge, K., Bostwick, D. G., and Stearns, M. E. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia,Prostate.29: 282–6, 1996.PubMedGoogle Scholar
  147. 147.
    Ross, J. S., Nazeer, T., Figge, H. L., Fisher, H. A., and Rifkin, M. D. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status, Am J Clin Pathol.104: 36–41, 1995.PubMedGoogle Scholar
  148. 148.
    Sinha, A. A., Wilson, M. J., Gleason, D. F., Reddy, P. K., Sameni, M., and Sloane, B. F. Immunohistochemical localization of cathepsin B in neoplastic human prostate, Prostate.26171–8, 1995PubMedGoogle Scholar
  149. 149.
    Mantzoros, C. S., Tzonou, A., Signorello, L. B., Stampfer, M., Trichopoulos, D., and Adami, H. O. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia [see comments], Br J Cancer.76: 1115–8, 1997.PubMedGoogle Scholar
  150. 150.
    Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study [see comments], Science.279: 563–6, 1998.PubMedGoogle Scholar
  151. 151.
    Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergstrom, R., Signorello, L. B., Lagiou, P., Adami, H. O., and Trichopoulos, D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study [see comments], J Natl Cancer Inst.90: 911–5, 1998.PubMedGoogle Scholar
  152. 152.
    Emmert-Buck, M. R., Vocke, C. D., Pozzatti, R. O., Duray, P. H., Jennings, S. B., Florence, C. D., Zhuang, Z., Bostwick, D. G., Liotta, L. A., and Linehan, W. M. Allelic loss on chromosome 8p12–21 in microdissected prostatic intraepithelial neoplasia, Cancer Res. 55: 2959–62, 1995.PubMedGoogle Scholar
  153. 153.
    Sakr, W. A., Macoska, J. A., Benson, P., Grignon, D. J., Wolman, S. R., Pontes, J. E., and Crissman, J. D. Allelic loss in locally metastatic, multisampled prostate cancer, Cancer Res.54: 3273–7, 1994.PubMedGoogle Scholar
  154. 154.
    Qian, J., Bostwick, D. G., Takahashi, S., Borell, T. J., Herath, J. F., Lieber, M. M., and Jenkins, R. B. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization, Cancer Res.55: 5408–14, 1995.PubMedGoogle Scholar
  155. 155.
    Macoska, J. A., Micale, M. A., Sakr, W. A., Benson, P. D., and Wolman, S. R. Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis, Genes Chromosomes Cancer.8: 88–97, 1993.PubMedGoogle Scholar
  156. 156.
    Takahashi, S., Qian, J., Brown, J. A., Alcaraz, A., Bostwick, D. G., Lieber, M. M., and Jenkins, R. B. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies, Cancer Res.54: 3574–9, 1994.PubMedGoogle Scholar
  157. 157.
    Alcaraz, A., Takahashi, S., Brown, J. A., Herath, J. F., Bergstralh, E. J., Larson-Keller, J. J., Lieber, M. M., and Jenkins, R. B. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer, Cancer Res.54: 3998–4002, 1994.PubMedGoogle Scholar
  158. 158.
    Bandyk, M. G., Zhao, L., Troncoso, P., Pisters, L. L., Palmer, J. L., von Eschenbach, A. C., Chung, L. W., and Liang, J. C. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression, Genes Chromosomes Cancer.9: 19–27, 1994.PubMedGoogle Scholar
  159. 159.
    Zenklusen, J. C., Thompson, J. C., Troncoso, P., Kagan, J., and Conti, C. J. Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1, Cancer Res.54: 6370–3, 1994.PubMedGoogle Scholar
  160. 160.
    Greene, D. R., Rogers, E., Wessels, E. C., Wheeler, T. M., Taylor, S. R., Santucci, R. A., Thompson, T. C., and Scardino, P. T. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features [see comments], J Urol. 151: 1301–7, 1994.PubMedGoogle Scholar
  161. 160.
    Brown, J. A., Alcaraz, A., Takahashi, S., Persons, D. L., Lieber, M. M., and Jenkins, R. B. Chromosomal aneusomies detected by fluorescent in situ hybridization analysis in clinically localized prostate carcinoma [see comments]J Urol1521157–62,1994.PubMedGoogle Scholar
  162. 162.
    Lee, W. H., Morton, R. A., Epstein, J. I., Brooks, J. D., Campbell, P. A., Bova, G. S., Hsieh, W. S., Isaacs, W. B., and Nelson, W. G. Cytidine methylation of regulatorysequences near the pi-class glutathione S-transferase gene accompanies humanprostatic carcinogenesis, Proc Natl Acad Sci USA. 91: 11733–7, 1994.PubMedGoogle Scholar
  163. 163.
    Taplin, M. E., Bub1ey, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer [see comments], N Engl J Med. 332: 1393–8, 1995.PubMedGoogle Scholar
  164. 164.
    Sandberg, A. A. Chromosomal abnormalities and related events in prostate cancer, Hum Pathol. 23: 368–80, 1992.PubMedGoogle Scholar
  165. 165.
    Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F., and Allred, D, C. p53is mutated in a subset of advanced-stage prostate cancers, Cancer Res. 53:3369–73. 1993.PubMedGoogle Scholar
  166. 166.
    Myers, R. B., Oelschlager, D., Srivastava, S., and Grizzle, W. E. Accumulation of thep53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas, Prostate. 25: 243–8, 1994.PubMedGoogle Scholar
  167. 167.
    Sarkar, F. H., Sakr, W., Li, Y. W W”Macoska, J., Ball, D. E., and Crissman, L. D, Analysis of retinoblastoma (RS) gene deletion in human prostatic carcinomas, Prostate. 21:145–52, 1992.PubMedGoogle Scholar
  168. 168.
    Brooks, J.D., Bova, G.S., and Isaacs, W.B. Allelic loss of the retinoblastoma genein primary human prostatic adenocarcinomas,Prostate. 26:35–9,1995.PubMedGoogle Scholar
  169. 169.
    Igawa, M., Ruksta1is, D. B., Tanabe, T., and Chodak, G. W. High levels of nm23 expression are related to cell proliferation in human prostate cancer, Cancer Res. 54: 1313–8, 1994.PubMedGoogle Scholar
  170. 170.
    Konishi, N., Nakaoka, S., Tsuzuki, T., Matsumoto, K., Kitahori, Y., Hiasa, Y., Urano, T., and Shiku, H. Expression of nm23-H 1 and nm23-H2 proteins in prostate carcinoma, Jpn J Cancer Res. 84: 1050–4, 1993.PubMedGoogle Scholar
  171. 171.
    Shen, R., Su, Z. Z., Olsson, C. A., and Fisher, P. B. Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display, Proc Natl Acad Sci USA. 92: 6778–82, 1995.PubMedGoogle Scholar
  172. 172.
    Dong, L. T., Lamb, P. W., Rinker-Schaeffer, C. W., Vukanovic, J., Ichikawa, T., Isaacs, L. T., and Barrett, J. C. Kail, a metastasis suppressor gene for prostate cancer on human chromosome I Ipl 1.2 [see comments], Science. 268: 884–6, 1995.PubMedGoogle Scholar
  173. 173.
    Rose, D. P., Boyar, A. P., and Wynder, E. L. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption, Cancer. 58: 2363–71, 1986.PubMedGoogle Scholar
  174. 174.
    West, D. W., Slattery, M. L., Robison, L. M., French, T. K., and Mahoney, A. W, Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors, Cancer Causes Control. 2, 85–94, 1991.PubMedGoogle Scholar
  175. 175.
    Lew, E. A. and Garfinkel, L. Variations in mortality by weight among 750,000 men and women, J Chronic Dis. 32: 563–76, 1979.PubMedGoogle Scholar
  176. 176.
    Liang, T. and Liao, S. Inhibition of steroid 5 alpha-reductase by specific aliphatic unsaturated fatty acids, Biochem J. 285: 557–62, 1992.PubMedGoogle Scholar
  177. 177.
    Wynder, E. L. and Andres, R. Disease prevention research at NIH: An Agenda for All. Workshop A: Diet and nutrition research as it relates to aging and chronic diseases, Prev Med. 23: 549–51, 1994.PubMedGoogle Scholar
  178. 178.
    Clark, J. and Thompson, I. M. Serum cholesterol as a risk factor for prostatic adenocarcinoma, South Med J, 87: 1141, 1994.PubMedGoogle Scholar
  179. 179.
    Fair, W. R., Fleshner, N. E., and Heston, W. Cancer of the prostate: a nutritional disease? [see comments], Urology. 50: 840–8, 1997.PubMedGoogle Scholar
  180. 180.
    Rose, D. P. Dietary fatty acids and prevention of hormone-responsive cancer, Proc Soc Exp Bioi Med. 216: 224–33, 1997.Google Scholar
  181. 181.
    Khan, W. A., Wang, Z. Y., Athar, M., Bickers, D. R., and Mukhtar, H, Inhibition of the skin tumorigenicity of (+/-)-7 beta,8 alpha-dihydroxy-9 alpha, 1 0 alpha-epoxy-134 Chemoprevention in Prostate Cancer 7,8,9,10-tetrahydrobenzo[a]pyrene by tannic acid, green tea polyphenols and quercetin in Sencar mice, Cancer Lett. 42:7–12, 1988.PubMedGoogle Scholar
  182. 182.
    Ahmad, N., Feyes, D. K., Nieminen, A L., Agarwal, R., and Mukhtar, H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells, J Nat! Cancer Inst. 89: 1881–6, 1997.PubMedGoogle Scholar
  183. 183.
    Conney, A H., Wang, Z. Y., Huang, M. T., Lou, Y. R., and Yang, C. S. Inhibitory effects of green and black tea on carcinogenesis, Proc. Amer. Assn. Ca. Res. 36: 74, 1995.Google Scholar
  184. 184.
    Wei, H., Bowen, R., Cai, Q., Bames, S., and Wang, Y. Antioxidant and antipromotional effects of the soybean isoflavone genistein, Proc Soc Exp Bioi Med. 208: 124–30, 1995.Google Scholar
  185. 185.
    Grant, W. B. An ecologic study of dietary links to prostate cancer, Altern Med Rev. 4. 162–9,1999.PubMedGoogle Scholar
  186. 186.
    Zackheim, H. S. Re: Tomatoes, tomato-based products, Iycopene, and prostate cancer: review of the epidemiologic literature [letter; comment], J Nat! Cancer Inst. 91. 1331,1999.PubMedGoogle Scholar
  187. 187.
    Giovannucci, E. and Clinton, S. K. Tomatoes, Iycopene, and prostate cancer, Proc Soc Exp Bioi Med. 218: 129–39, 1998.Google Scholar
  188. 188.
    Rao, A V., Fleshner, N., and Agarwal, S. Serum and tissue Iycopene and biomarkers of oxidation in prostate cancer patients: a case-control study, Nutr Cancer. 33. 159–64, 1999.PubMedGoogle Scholar
  189. 189.
    Kucuk, 0., Sakr, W., and Sarkar, F. Lycopene supplementation in men with localized prostate cancer modulates grade and volume of PIN and tumor, level of serum PSA and biomarkers of cell growth, differentiation, and apoptosis, Proc. Am. Assoc. Ca. Res. 40: 409,1999.Google Scholar
  190. 190.
    Skowronski, R. J., Peehl, D. M., and Feldman, D. Vitamin 0 and prostate cancer: 1,25 dihydroxyvitamin 03 receptors and actions in human prostate cancer cell lines, Endocrinology. 132: 1952–60, 1993.PubMedGoogle Scholar
  191. 191.
    Ingles, S. A, ‘Ross, R. K., Yu, M. c., Irvine, R. A, La Pera, G., Haile, R. W., and Coetzee, G. A Association of prostate cancer risk with genetic polymorph isms in vitamin 0 receptor and androgen receptor [see comments], J Natl Cancer Inst. 89. 166–70,1997.PubMedGoogle Scholar
  192. 192.
    de Vos, S., Holden, S., Heber, D., Elstner, E., Binderup, L., Uskokovic, M., Rude, B., Chen, D. L., Le, J., Cho, S. K., and Koeffier, H. P. Effects of potent vitamin 03 analogs on clonal proliferation of human prostate cancer cell lines, Prostate. 31: 77–83, 1997.PubMedGoogle Scholar
  193. 193.
    Schwartz, G. G., Wang, M. H., Zang, M., Singh, R. K., and Siegal, G. P. I alpha,25-Dihydroxyvitamin 0 (calcitriol) inhibits the invasiveness of human prostate cancer cells, Cancer Epidemiol Biomarkers Prevo 6: 727–32, 1997.Google Scholar
  194. 194.
    Schwartz, G. G. and Hulka, B. S. Is vitamin 0 deficiency a risk factor for prostate cancer? (Hypothesis), Anticancer Res. 10: 1307–11, 1990.PubMedGoogle Scholar
  195. 195.
    Corder, E. H., Guess, H. A, Hulka, B. S., Friedman, G. D., Sadler, M., Vollmer, R. T., Lobaugh, B., Drezner, M. K., Vogel man, J. H., and Orentreich, N. Vitamin D and prostate cancer: a prediagnostic study with stored sera [see comments], Cancer Epidemiol Biomarkers Prevo 2: 467–72, 1993.Google Scholar
  196. 196.
    Pasquali, D., Thaller, c., and Eichele, G. Abnormal level of retinoic acid in prostate cancer tissues, J Clin Endocrinol Metab. 81: 2186–91, 1996.PubMedGoogle Scholar
  197. 197.
    Hsing, A W., McLaughlin, J. K., Schuman, L. M., Bjelke, E., Gridley, G., Wacholder, S., Chien, H. T., and Blot, W. J. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study [see comments], Cancer Res. 50: 6836–40, 1990.PubMedGoogle Scholar
  198. 198.
    Eichholzer, M., Stahelin, H. B., Gey, K. F., Ludin, E., and Bernasconi, F. Prediction CANCER CHEMOPREVENTION 135 of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study, Int J Cancer. 66: 145–50, 1996.PubMedGoogle Scholar
  199. 199.
    Hayes, R. B., Bogdanovicz, J. F., Schroeder, F. H., De Bruijn, A, Raatgever, J. W., Van der Maas, P. 1., Oishi, K., and Yoshida, O. Serum retinol and prostate cancer, Cancer. 62: 2021–6, 1988.PubMedGoogle Scholar
  200. 200.
    Albanes, D., Heinonen, O. P., Huttunen, J. K., Taylor, P. R., Virtamo, J., Edwards, B. K., Haapakoski, J., Rautalahti, M., Hartman, A M., Palmgren, J., and et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha- Tocopherol Beta-Carotene Cancer Prevention Study, Am J Clin Nutr. 62: 1427S–1430S, 1995.PubMedGoogle Scholar
  201. 201.
    Brawer, M. K. and Ellis, W. J. Chemoprevention for prostate cancer, Cancer. 75: 1783–1789,1995.Google Scholar
  202. 202.
    Benedict, W. F. and Jones, P. A Inhibition of transformation and oncogenic progression by ascorbic acid, a possible role in chemoprevention. In: M. S. Arnot, J. Van Eys, and Y. M. Wang (eds.), Molecular interrelations of nutrition and cancer, pp. 351. New York: Raven Press, 1982.Google Scholar
  203. 203.
    Maramag, C., Menon, M., Balaji, K. C., Reddy, P. G., and Laxmanan, S. Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability, and DNA synthesis, Prostate. 32: 188–95, 1997.PubMedGoogle Scholar
  204. 204.
    National Academy of Sciences, F. a. N. B. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington: National Academy Press, 2000.Google Scholar
  205. 205.
    Fleshner, N., Fair, W. R., Huryk, R., and Heston, W. D. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice, J Uro!. 161: 1651–4, 1999.Google Scholar
  206. 206.
    Moyad, M. A, Brumfield, S. K., and Pienta, K. J. Vitamin E, alpha-and gamma-tocopherol, and prostate cancer, Semin Urol Oncol. 17: 85–90, 1999.PubMedGoogle Scholar
  207. 207.
    Hartman, T. J., Albanes, D., Pietinen, P., Hartman, A. M., Rautalahti, M., Tangrea, J. A, and Taylor, P. R. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study, Cancer Epidemiol Biomarkers Prevo 7: 335–40, 1998.Google Scholar
  208. 208.
    Eichholzer, M., Stahelin, H. B., Ludin, E., and Bernasconi, F. Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer: seventeen-year follow-up ofthe prospective basal study, Prostate. 38: 189–98, 1999.PubMedGoogle Scholar
  209. 209.
    Hsing, A W., Comstock, G. W., Abbey, H., and Polk, B. F. Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer, I Nat! Cancer Ins!. 82: 941–6, 1990.Google Scholar
  210. 210.
    Combs, G. F., Ir. and Gray, W. P. Chemopreventive agents: selenium, Pharmacol Ther. 79: 179–92, 1998.PubMedGoogle Scholar
  211. 211.
    Heston, W. D., Kadmon, D., Lazan, D. W., and Fair, W. R. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-ditluoromethylornithine, Prostate. 3: 383–9, 1982.PubMedGoogle Scholar
  212. 212.
    Danzin, C., Claverie, N., Wagner, I., Grove, I., and Koch-Weser, I. Effect on prostatic growth of 2-ditluoromethylornithine, an effective inhibitor of ornithine decarboxylase, Biochem J. 202: 175–81, 1982.PubMedGoogle Scholar
  213. 213.
    Hovenian, M. and Deming, C. The heterologous growth of cancer of the human prostate, Surg. Gynec. and Obs!. 86: 29, 1948.Google Scholar
  214. 214.
    Tsukamoto, S., Akaza, H., Onozawa, M., Shirai, T., and Ideyama, Y. A five-alpha reductase inhibitor or an anti androgen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats, Cancer. 82: 531–7, 1998.PubMedGoogle Scholar
  215. 215.
    Marks, L. S., Partin, A. W., Gormley, G. I., Dorey, F. J., Shery, E. D., Garris, I. B., Subong, E. N., Stoner, E., and deKernion, J. B. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia [see comments], I Urol. 157: 2171–8,1997.Google Scholar
  216. 216.
    Brawley, O. W., Ford, L. G., Thompson, I., Perlman, I. A, and Kramer, B. S. 5-Alpha-reductase inhibition and prostate cancer prevention, Cancer Epidemiol 136 Chemoprevention in Prostate Cancer Biomarkers Prevo 3: 177–82, 1994.Google Scholar
  217. 217.
    Rittmaster, R. S. Finasteride, N Engl J Med. 330: 120–5, 1994.PubMedGoogle Scholar
  218. 218.
    Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., and Padley, R. J. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs CooperativeStudies Benign Prostatic Hyperplasia Study Group [see comments], N Engl J Med. 335. 533–9, 1996.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Chadi Nabhan
  • Raymond Bergan

There are no affiliations available

Personalised recommendations